NKTX
NkartaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The bull case is that Nkarta has enough cash to reach its first meaningful autoimmune data, while protocol amendments that expand outpatient/community dosing and re-dosing may accelerate enrollment and improve the eventual dataset quality.[#SEC-8K-2026-05-12]
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Clinical risk is dominant because Nkarta still has not reported the initial Ntrust-1/Ntrust-2 efficacy dataset that would validate depth and durability of response.[#SEC-8K-2026-05-12]
Momentum
57
Value
41
Sentiment
43
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.40 · Bull $4.20 · Bear $1.30
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $11.33
Why
Momentum57 · Δ7d +3.4
Value41 · Δ7d -0.1
Sentiment43 · Δ7d -20.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
57
26% active weight
Current posture
7d trendSoftening
Δ7d
+3.4
Δ21d
-39.5
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
43
34% active weight
Current posture
7d trendSoftening
Δ7d
-20.2
Δ21d
-16.7
Why this grade
Composite grade D. Momentum 56.6 / Value 41.1 / Sentiment 43.0
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$186.02M
Beta
0.55
Shares Out
71.55M
P/E (TTM) · Derived
-1.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.18
Rev YoY
-100.0%
EPS YoY
-13.4%
Gross Margin
-
Op Margin
-
Net Debt
-$199.86M
Current Ratio
12.96
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology